Securities Class Action Lawsuit Against Revance Therapeutics, Inc. (RVNC) - Contact Kaplan Fox Before Deadline on March 4, 2025
NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. ('Revance' or the 'Company') (NASDAQ: RVNC) on behalf of investors that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024 (the 'Class Period').
If you are an investor in Revance and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003.
DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than March 4, 2025 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process.
Revance is a biotechnology company and the distributor of certain dermal filler products pursuant to an exclusive distribution agreement with Teoxane SA.
On August 12, 2024, Revance issued a press release announcing that the Company had entered into a merger agreement with Crown Laboratories ('Crown'). Under the terms of the agreement, the press release indicated that Crown would commence a tender offer to acquire all outstanding shares of Revance's common stock for $6.66 per share (the 'Tender Offer').
Then, on September 23, 2024, Revance disclosed that it 'received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA.' Due to the dispute with Teoxane, the Company advised that Crown's Tender Offer had been delayed until at least October 4, 2024.
On this news, the price of Revance stock fell $.445 per share, or 7.66%, to close at $5.365 per share on September 23, 2024.
Then, on December 9, 2024, the Company disclosed that Crown and Revance had amended their merger agreement, and that Crown would commence a tender offer on December 12, 2024 to acquire all outstanding shares of Revance common stock for $3.10 per share, more than 50% lower than the original purchase price.
On this news, the price of Revance stock fell $.79 per share, or 20.68%, to close at $3.03 per share on December 9, 2024.
The complaint alleges, among other things, that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that (i) Revance was in material breach of the Distribution Agreement; (ii) the foregoing subjected the Company to an increased risk of litigation, as well as monetary and reputational harm; and (iii) all the foregoing increased the risk that the Tender Offer would be delayed and/or amended.
WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Pamela A. Mayer
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(646) 315-9003
[email protected]
Laurence D. King
1999 Harrison Street, Suite 1560
Oakland, California 94612
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
43 minutes ago
- Yahoo
1 Magnificent Growth Stock Down 75% to Buy Hand Over Fist in June
Docusign stock was a pandemic darling, but the stock couldn't sustain its momentum once social distancing efforts ended. Docusign stock is down 75% from its 2021 peak, but the company continues to deliver steady revenue growth and its profits are soaring. The stock now trades at an attractive valuation relative to its history, and artificial intelligence (AI) could fuel its next move higher. 10 stocks we like better than Docusign › Docusign (NASDAQ: DOCU) stock soared to a peak of $310 in 2021 on the back of an incredible spike in demand for the company's suite of digital document tools, which helped businesses keep their operations running smoothly in the face of the pandemic's lockdowns and social distancing restrictions. Since that pandemic tailwind subsided, the stock has slumped by 75% from that peak, but the business itself is still generating steady revenue growth, and its profits are currently soaring. Plus, Docusign is experiencing strong demand for its new Intelligent Agreement Management (IAM) platform, which is powered by artificial intelligence (AI). On June 6, Docusign reported results for its fiscal 2026 first quarter (which ended April 30), and management increased its full-year revenue guidance, which signals clear momentum across the business. Here's why investors might want to buy the stock now. Docusign transformed its product portfolio over the past year. It still helps businesses create, negotiate, and close contracts, but AI is now at the center of that mission. The IAM platform is designed to solve the "agreement trap" more effectively. According to a study by Deloitte, the inefficiencies caused by poor contract management processes result in $2 trillion in lost economic value every year. That represents a massive opportunity for Docusign. IAM features a growing list of revolutionary products. Navigator, for example, is a digital repository where businesses can store their agreements. It uses AI to extract critical details from each document so they are discoverable via its search function, which saves employees from spending valuable time digging through contracts manually. Then there is AI-Assisted Review, which can help employees rapidly identify problematic clauses or even opportunities within each agreement. Businesses can also set pre-approved standards so the tool knows exactly what to look for, which reduces the time it takes to reach a final deal. Maestro ties the IAM platform together with a series of no-code tools that allow businesses to automate agreement workflows. They can drag-and-drop features like webforms, ID verification, and eSignature into each contract, which saves significant amounts of time and money compared to manual processes, especially when creating agreements at scale. At the end of its first quarter of fiscal 2026, Docusign had 1.7 million paying enterprise customers and more than 1 billion individual users. The company launched the IAM platform in April 2024, and it already has 10,000 paying enterprise customers who have used it to process tens of millions of agreements so far. During the quarter, IAM sales in international markets soared by 50% compared to fiscal 2025 Q4, which highlights the platform's serious momentum. Docusign generated $763.7 million in total revenue during fiscal Q1. That was an 8% increase from the year-ago period, and comfortably above the $749 million that had been the high end of management's guidance range. In fact, the strong result prompted the company to revise its revenue forecast for fiscal 2026 upward by $22 million to $3.163 billion at the high end of the range. In my opinion, Docusign could be growing its revenue more quickly, but it's carefully managing its costs to improve its bottom line rather than investing more heavily in customer acquisition. The company's total operating expenses only increased by 1.6% year over year during the first quarter, which was a much slower rate than its revenue increased. As a result, its net income surged by 113.5% to $72.1 million on a GAAP (generally accepted accounting principles) basis. Docusign also achieved a solid result in the bottom line on a non-GAAP basis, which excludes one-off and non-cash expenses like stock-based compensation. Non-GAAP net income came in at $190.8 million, which was an increase of 10% from the year-ago period. Non-GAAP results can be particularly useful for investors to consider when a company incurs a large one-off benefit or expense. For example, during Docusign's fiscal 2025 second quarter, it reported a large one-off tax benefit worth $816 million which massively skewed its net income, so its GAAP earnings weren't a true reflection of the performance of its actual business. When Docusign stock peaked in 2021, its price-to-sales (P/S) ratio soared to an unsustainable level of around 40. The 75% decline in its stock since then, combined with the company's steady revenue growth, has pushed its P/S ratio down to a more reasonable 5.4. In fact, that's a 56% discount to its average P/S ratio of 12.5 since the stock went public in 2018. Docusign also trades at a price-to-earnings (P/E) ratio of just 14.6, which makes it far cheaper than the S&P 500 index, which is trading at a P/E ratio of 23.3. However, that is based on Docusign's trailing 12-month GAAP earnings per share (EPS) which, as I mentioned earlier, was skewed by a one-off tax benefit from the second quarter of fiscal 2025. Therefore, the P/S ratio might be a better way to value the stock right now, but no matter which way you slice it, Docusign's valuation appears attractive. The picture looks even better when you factor in the company's addressable market, which could be worth $50 billion according to an estimate issued by management last year. Based on its current revenue, it has barely scratched the surface of that opportunity. In summary, Docusign stock can offer investors unique exposure to the AI revolution, and its combination of steady revenue growth and soaring profits could make it a great addition to any diversified portfolio at the current price. Before you buy stock in Docusign, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Docusign wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $655,255!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $888,780!* Now, it's worth noting Stock Advisor's total average return is 999% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Anthony Di Pizio has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Docusign. The Motley Fool has a disclosure policy. 1 Magnificent Growth Stock Down 75% to Buy Hand Over Fist in June was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Citi Reaffirms Buy on Broadcom (AVGO) Amid Surging AI Revenue
Broadcom Inc. (NASDAQ:AVGO) is one of the 10 best tech stocks to buy according to billionaires right now. On June 9, a Citi analyst raised his price target on Broadcom from $276 to $285 while maintaining a Buy rating. This revision follows Broadcom's second-quarter results, which showed continued strength in AI-related revenue, although overall performance was mixed, as per the analyst, due to some pressure on margins. Broadcom continues to benefit from growing demand in the artificial intelligence space, which remains a key driver of topline performance. The company reported Q2 FY 2025 revenue of $15.0 billion, up 20% year-over-year supported by strong AI semiconductor sales and contributions from VMware. Adjusted EBITDA rose 35% year-over-year to $10.0 billion, implying an EBITDA margin of 67%. A worker assembling the inner circuitry of a semiconductor product. AI-related revenue reached $4.4 billion in Q2, growing 46% year-over-year, driven primarily by demand for AI networking solutions. Management expects this momentum to carry into Q3, with AI semiconductor revenue projected to reach $5.1 billion. This growth is supported by continued investment by hyperscale customers. Looking ahead, Broadcom guided for Q3 FY25 revenue of approximately $15.8 billion and an adjusted EBITDA margin of at least 66% of revenue, which is slightly below versus Q2. However, the company's margin outlook raised some concerns. According to the analyst, an increased contribution of semiconductor sales in total sales has put pressure on profitability. In response, management has adjusted its guidance, which indicates a slightly lower margin in the near term. Broadcom Inc. (NASDAQ:AVGO) is a global technology company that designs, develops, and supplies a wide range of semiconductor and infrastructure software solutions. The company's products play a crucial role in enterprise and data center networking, broadband access, storage systems, smartphones, and wireless communications. Broadcom's extensive portfolio includes solutions for data center networking, storage, and security, making it a key player in the data center ecosystem. While we acknowledge the potential of AVGO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Raymond James Resumes Coverage on Disc Medicine (IRON) With a Strong Buy Rating
Disc Medicine, Inc. (NASDAQ:IRON) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On June 11, analysts from Raymond James resumed coverage of Disc Medicine, Inc. (NASDAQ:IRON) with a strong Buy rating and a price target of $89. The resumed coverage comes as the company released its research note on Biotech names. The firm highlighted a favorable risk/reward profile in the biotech sector. It noted that while companies with a high probability of success for lead assets inspire higher conviction, investments in less de-risked assets like Disc Medicine, Inc. (NASDAQ:IRON) could yield the most outsized returns. The firm sees more than $1 billion potential for the company's drug bitopertin, with an expected market penetration of about 30%-35%, owing to its disease-modifying agent capabilities X-linked protoporphyria. A scientist in a laboratory setting examining a sample of blood with a microscope. Disc Medicine, Inc. (NASDAQ:IRON) is a clinical-stage biopharmaceutical company focused on discovering therapies for serious hematologic diseases. Its pipeline includes drug candidates like bitopertin for erythropoietic porphyrias and Diamond-Blackfan Anemia, DISC-0974 for anemia related to myelofibrosis and chronic kidney disease, and DISC-3405 for polycythemia vera and other blood disorders. While we acknowledge the potential of IRON as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
